377 related articles for article (PubMed ID: 15744236)
21. Antitumor activity of cytokine-induced killer cells against human lung cancer.
Kim HM; Lim J; Park SK; Kang JS; Lee K; Lee CW; Lee KH; Yun MJ; Yang KH; Han G; Kwon SW; Kim Y; Han SB
Int Immunopharmacol; 2007 Dec; 7(13):1802-7. PubMed ID: 17996691
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
24. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
Sun Z; Shi L; Zhang H; Shao Y; Wang Y; Lin Y; Li X; Bai C
Clin Immunol; 2011 Jan; 138(1):23-32. PubMed ID: 21041120
[TBL] [Abstract][Full Text] [Related]
25. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
Wu C; Jiang J; Shi L; Xu N
Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
[TBL] [Abstract][Full Text] [Related]
26. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
28. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period.
Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL
Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022
[TBL] [Abstract][Full Text] [Related]
29. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
30. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
31. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies.
Niu Q; Wang W; Li Y; Qin S; Wang Y; Wan G; Guan J; Zhu W
Int Immunopharmacol; 2011 Apr; 11(4):449-56. PubMed ID: 21215350
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Lim J; Kang JS; Park SK; Lee K; Kim JY; Kim YJ; Hong JT; Kim Y; Han SB
Int Immunopharmacol; 2009 Mar; 9(3):375-80. PubMed ID: 19105981
[TBL] [Abstract][Full Text] [Related]
33. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
[TBL] [Abstract][Full Text] [Related]
34. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
36. [Large-capacity expanded cytoline-induced killer cells and its cytotoxic activity].
Shi Y; Yu J; Cen X; Zhu P; Ma M
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2001 Mar; 18(1):94-6. PubMed ID: 11332127
[TBL] [Abstract][Full Text] [Related]
37. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
38. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.
Introna M; Franceschetti M; Ciocca A; Borleri G; Conti E; Golay J; Rambaldi A
Bone Marrow Transplant; 2006 Nov; 38(9):621-7. PubMed ID: 16980990
[TBL] [Abstract][Full Text] [Related]
39. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
[TBL] [Abstract][Full Text] [Related]
40. Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo.
Wang J; He M; Shi W; Sha H; Feng J; Wang S; Wang Y
Cancer Invest; 2009 Mar; 27(3):244-50. PubMed ID: 19194830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]